|
| Author (yr) | Setting | Pts | Treatment | Results | Toxicity |
|
| Asahina et al. (2006) [44] | Chemonaive, EGFR mutation | 16 | Gefitinib 250 mg | RR: 75%; PFS: 8.9 months, 1 yr OS: 88% | Rash, hepatotoxicity |
| Inoue et al. (2006) [45] | Chemonaive, EGFR mutation | 16 | Gefitinib 250 mg | RR: 75%; PFS: 9.7 months; 1 yr OS: 88% | Skin toxicity, stomatitis, diarrhea |
| Yang et al. (2008) [46] | Chemonaive, EGFR mutation | 55 | Gefitinib 250 mg | RR: 84.2%; PFS: 8.9 months, OS: 24 months | Skin toxicity, hepatotoxicity, diarrhea |
| Sequist et al. (2008) [47] | Chemonaive, EGFR mutation | 31 | Gefitinib 250 mg | RR: 55%; PFS: 9.2 months, OS: 17.5 months | Skin toxicity, diarrhea, nausea, fatigue |
| Sutani et al. (2006) [48] | 1st-2nd line, EGFR mutation | 27 | Gefitinib 250 mg | RR: 78%; PFS: 9.4 months, OS: 15.4 months | Diarrhea, skin toxicity |
| Yoshida et al. (2007) [49] | Chemonaive, EGFR mutation | 21 | Gefitinib 250 mg | RR: 90%; TTP: 7.7 months | Skin toxicity, diarrhea, hepatotoxicity |
| Sunaga et al. (2007) [50] | Chemonaive, EGFR mutation | 19 | Gefitinib 250 mg | RR: 76%; DSR: 90%; TTP: 12.9 months | Skin toxicity |
| Tamura et al. (2008) [51] | Chemonaive, EGFR mutation | 27 | Gefitinib 250 mg | RR: 75%; DSR: 96%; PFS: 11.5 months,1 yr OS: 79% | Skin toxicity, hepatotoxicity, stomatitis, diarrhea |
| Sugio et al. (2009) [52] | Chemonaive, EGFR mutation | 19 | Gefitinib 250 mg | RR: 63.2%; PFS 7.1 months, OS: 20 months | Skin toxicity, nail change |
| Inoue et al. (2009) [53] | Chemonaive, EGFR mutation and poor PS | 30 | Gefitinib 250 mg | RR: 66%, DSR 90%, PFS 6.5 months, OS 17.8 months, PS improvement rate: 79% | Hepatotoxicity, anemia, skin toxicity |
| Cappuzzo et al. (2007) [54] | FISH positive or never smokers | 42 | Gefitinib 250 mg | RR: 47.6%; PFS: 6.4 months; 1 y OS: 64%. | Skin toxicity, diarrhea |
| West et al. (2006) [55] | Brochoalveolar carcinoma, 1st-2nd line | 91 | Gefitinib 500 mg | RR: 9% and OS 13 months in 2nd line; RR 17% and OS 13 months in 1st line | Skin toxicity, diarrhea |
| D. H. Lee et al. (2005) [56] | Adenocarcinoma and never smokers | 37 | Gefitinib 250 mg | RR: 69%; PFS: 33 weeks; 1 yr OS: 73% | Skin toxicity, diarrhea |
|
